News & Events

Simtra BioPharma Solutions nnounces the publication of its inaugural Sustainability Report for the year ended December 31, 2024.

On the latest episode of Drug Digest, Lidia Serina, Ph.D., Head of Development Services at Simtra BioPharma Solutions, discusses three advanced modalities that she believes are shaping the pharmaceutical industry, including antibody-drug conjugates (ADCs) for oncology treatments. 

 

Simtra is driving the future of sterile injectable manufacturing with cutting-edge investments in ADCs, expanded fill-finish capacity, and enhanced development services. As the demand for complex therapies grows, our commitment to quality, efficiency, and patient-centered innovation has never been stronger.

DCAT Week 2025, Lidia Serina, Ph.D., Head of Development Services at Simtra BioPharma Solutions, shares insights into the challenges of maintaining aseptic integrity and stability in sterile injectable manufacturing with BioPharm International.

Simtra BioPharma Solutions expands capabilities with $14M investment for accelerated development and manufacturing of antibody-drug conjugates (ADCs) as part of the scaling of its development services business.

Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is pleased to announce the appointment of Dr. Mike Schäfers, Ph.D., as Chief Commercial Officer and Head of Business Development.

Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is pleased to announce the appointment of Dr. Lidia Serina, Ph.D., as Head of Development Services.

Simtra BioPharma Solutions (Simtra), a premier injectable contract development and manufacturing organization (CDMO), today announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.

Simtra BioPharma Solutions (Simtra), a leading sterile injectable contract development and manufacturing organization (CDMO), proudly announces the establishment of its new corporate headquarters at 400 Interpace Parkway, Building C, Suite 270, Parsippany, New Jersey.